

Axel Hauschild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2975744/publications.pdf>

Version: 2024-02-01

76
papers

15,278
citations

101543

36
h-index

69250

77
g-index

81
all docs

81
docs citations

81
times ranked

15562
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	27.0	4,074
2	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 358-365.	13.7	2,691
3	Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2171-2179.	27.0	1,201
4	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	27.0	1,192
5	Melanoma. <i>Lancet, The</i> , 2018, 392, 971-984.	13.7	1,016
6	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
7	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , 2019, 113, 47-54.	2.8	300
8	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017, 17, 332.	2.6	291
9	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2010, 46, 270-283.	2.8	284
10	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017, 86, 334-348.	2.8	212
11	Deep neural networks are superior to dermatologists in melanoma image classification. <i>European Journal of Cancer</i> , 2019, 119, 11-17.	2.8	212
12	Superior skin cancer classification by the combination of human and artificial intelligence. <i>European Journal of Cancer</i> , 2019, 120, 114-121.	2.8	197
13	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , 2019, 111, 148-154.	2.8	197
14	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	13.7	188
15	Ipilimumab in patients with cancer and the management of dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 161-169.	1.2	170
16	Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. <i>European Journal of Cancer</i> , 2014, 50, 774-783.	2.8	154
17	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021, 22, 848-857.	10.7	150
18	Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 404-412.	10.7	149

#	ARTICLE	IF	CITATIONS
19	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. <i>European Journal of Cancer</i> , 2019, 119, 57-65.	2.8	134
20	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 1218-1229.	3.7	125
21	Practical guidelines for the management of interferon- α 2b side effects in patients receiving adjuvant treatment for melanoma. <i>Cancer</i> , 2008, 112, 982-994.	4.1	116
22	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. <i>European Journal of Cancer</i> , 2021, 156, 202-216.	2.8	115
23	Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. <i>British Journal of Dermatology</i> , 2009, 160, 1066-1074.	1.5	108
24	Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. <i>Melanoma Research</i> , 1999, 9, 155-162.	1.2	107
25	Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. <i>British Journal of Dermatology</i> , 1999, 140, 1065-1071.	1.5	105
26	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. <i>Annals of Oncology</i> , 2011, 22, 524-535.	1.2	104
27	Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. <i>European Journal of Cancer</i> , 2019, 111, 30-37.	2.8	104
28	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1944-1956.	2.4	94
29	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	2.8	92
30	Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis. <i>Journal of Clinical Oncology</i> , 2003, 21, 2883-2888.	1.6	68
31	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	1.2	67
32	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. <i>European Journal of Cancer</i> , 2022, 171, 203-231.	2.8	51
33	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolimmunology</i> , 2017, 6, e1338237.	4.6	47
34	Artificial Intelligence and Its Effect on Dermatologists's Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e18091.	4.3	45
35	Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 8510-8510.	1.6	44
36	Explainable artificial intelligence in skin cancer recognition: A systematic review. <i>European Journal of Cancer</i> , 2022, 167, 54-69.	2.8	42

#	ARTICLE	IF	CITATIONS
37	Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. <i>Experimental Dermatology</i> , 2009, 18, 116-121.	2.9	41
38	Eruptive vellus hair cysts and steatocystoma multiplex. Variants of one entity?. <i>British Journal of Dermatology</i> , 1996, 134, 365-367.	1.5	37
39	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e23436.	4.3	36
40	Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. <i>European Journal of Cancer</i> , 2021, 154, 227-234.	2.8	36
41	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e20708.	4.3	35
42	A benchmark for neural network robustness in skin cancer classification. <i>European Journal of Cancer</i> , 2021, 155, 191-199.	2.8	34
43	Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. <i>European Journal of Cancer</i> , 2019, 119, 30-34.	2.8	33
44	To excise or not: impact of MelaFind on German dermatologists'™ decisions to biopsy atypical lesions. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 606-614.	0.8	32
45	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1547-1559.	4.2	32
46	Robustness of convolutional neural networks in recognition of pigmented skin lesions. <i>European Journal of Cancer</i> , 2021, 145, 81-91.	2.8	32
47	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 4077-4084.	1.6	29
48	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
49	Adjuvant Interferon Alfa for Melanoma: New Evidence-Based Treatment Recommendations?. <i>Current Oncology</i> , 2009, 16, 3-6.	2.2	27
50	Sorafenib and pegylated interferon- β 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. <i>Annals of Oncology</i> , 2011, 22, 1667-1674.	1.2	27
51	Sentinel node biopsy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 99-106.	2.8	23
52	The evolving field of Dermatologic Oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV and UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
53	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018, 27, e12901.	1.5	19
54	Adverse events 2.0 Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	2.8	19

#	ARTICLE	IF	CITATIONS
55	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 8044-8044.	1.6	17
56	Surgical Standards in the Primary Care of Melanoma Patients. <i>Oncology Research and Treatment</i> , 2003, 26, 218-222.	1.2	16
57	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018, 28, 775-783.	0.6	16
58	Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 117-121.	1.8	14
59	Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions. <i>British Journal of Dermatology</i> , 2015, 173, 1277-1279.	1.5	10
60	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany – The non-interventional study NIELS. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1678-1685.	2.4	10
61	Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients. <i>Recent Results in Cancer Research</i> , 2001, 158, 169-177.	1.8	10
62	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA9012-LBA9012.	1.6	8
63	Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas. <i>American Journal of Pathology</i> , 1989, 135, 177-84.	3.8	8
64	The Impact of Multispectral Digital Skin Lesion Analysis on German Dermatologist Decisions to Biopsy Atypical Pigmented Lesions with Clinical Characteristics of Melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 27-9.	0.1	5
65	Individualized therapy of disseminated cancer using malignant melanoma as a model. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 253-256.	5.9	4
66	Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”. <i>European Journal of Cancer</i> , 2020, 131, 100-103.	2.8	4
67	Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MKIE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e526-e529.	2.4	4
68	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	3.7	4
69	New Promises in the Adjuvant, and Palliative Treatment of Melanoma. <i>Cancer Treatment and Research</i> , 2007, 135, 277-292.	0.5	3
70	Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockade-Related complications?. <i>European Journal of Cancer</i> , 2021, 153, 72-73.	2.8	2
71	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA9012-LBA9012.	1.6	2
72	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA9012-LBA9012.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma. <i>European Journal of Cancer</i> , 2021, , .	2.8	2
74	Multiple painful leiomyomas of the skin: a novel therapy with sympathicolysis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1997, 9, 262-265.	2.4	1
75	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	1.6	1
76	Response to: Comment on "Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines". <i>European Journal of Cancer</i> , 2020, 140, 154-157.	2.8	1